Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia by unknown
RESEARCH Open Access
Pharmacological inhibition of LSD1 for the
treatment of MLL-rearranged leukemia
Zizhen Feng1, Yuan Yao1, Chao Zhou1, Fengju Chen2, Fangrui Wu1, Liping Wei1, Wei Liu3,4, Shuo Dong5,
Michele Redell3,4, Qianxing Mo2,5 and Yongcheng Song1,2*
Abstract
Background: Mixed lineage leukemia (MLL) gene translocations are found in ~75 % infant and 10 % adult acute
leukemia, showing a poor prognosis. Lysine-specific demethylase 1 (LSD1) has recently been implicated to be a
drug target for this subtype of leukemia. More studies using potent LSD1 inhibitors against MLL-rearranged
leukemia are needed.
Methods: LSD1 inhibitors were examined for their biochemical and biological activities against LSD1 and
MLL-rearranged leukemia as well as other cancer cells.
Results: Potent LSD1 inhibitors with biochemical IC50 values of 9.8–77 nM were found to strongly inhibit
proliferation of MLL-rearranged leukemia cells with EC50 of 10–320 nM, while these compounds are generally
non-cytotoxic to several other tumor cells. LSD1 inhibition increased histone H3 lysine 4 (H3K4) methylation,
downregulated expression of several leukemia-relevant genes, induced apoptosis and differentiation, and inhibited
self-renewal of stem-like leukemia cells. Moreover, LSD1 inhibitors worked synergistically with inhibition of DOT1L,
a histone H3 lysine 79 (H3K79) methyltransferase, against MLL-rearranged leukemia. The most potent LSD1 inhibitor
showed significant in vivo activity in a systemic mouse model of MLL-rearranged leukemia without overt toxicities.
Mechanistically, LSD1 inhibitors caused significant upregulation of several pathways that promote hematopoietic
differentiation and apoptosis.
Conclusions: LSD1 is a drug target for MLL-rearranged leukemia, and LSD1 inhibitors are potential therapeutics for
the malignancy.
Keywords: MLL-rearranged leukemia, Lysine-specific demethylase 1, Enzyme inhibitor, Drug discovery, Leukemia
therapeutics
Background
Acute leukemia, including acute lymphoblastic leukemia
(ALL) and acute myeloid leukemia (AML), afflicts
people of all ages, and it is the most common cancer af-
fecting children under the age of 15. Although certain
subtypes of leukemia, e.g., childhood ALL, have achieved
high cure rates, the 5-year survival rates for the majority
of acute leukemia (mostly AML) patients are still low
[1]. With a few exceptions, current treatments are
conventional chemotherapeutics, which non-selectively
kill all rapidly proliferating cells including normal stem/
progenitor cells in the bone marrow and other organs
(e.g., intestines). This causes severe toxicities and side
effects, usually limiting the efficacy of these drugs.
Biomarkers, such as mixed lineage leukemia (MLL) gene
translocation and MEF2C [2], are frequently used to
classify molecular subtypes of AML, predict prognosis,
and determine therapeutic regimes. Acute leukemia
carrying an MLL gene translocation accounts for the
majority (~75 %) of leukemia in infants as well as ~10 %
in children and adults. This subtype of leukemia shows a
poor prognosis, with 5-year event-free survival being
only ~40 % [3–5]. Intensified chemotherapy causes
increased toxicity to patients without a significant
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improvement of survival. There is therefore a pressing
need to find new therapeutics.
MLL is a large protein (3969 amino acid residues) with
multiple domains (Additional file 1: Figure S1A and B).
Its C-terminal SET domain, a homolog of Drosophila
trithorax, is a histone H3 lysine 4 (H3K4) methyltrans-
ferase. The N-terminal AT hook domain recognizes the
promoters or enhancers of certain genes and directs the
methylation loci for the SET domain [6]. Studies show
that methylated H3K4 (H3K4me1, 2, or 3) is associated
with active transcription of many genes including Hox
genes important for hematopoiesis [7, 8]. However,
overexpression of certain Hox genes, such as HoxA9,
leads to leukemogenesis [9]. Cellular H3K4 methylation
is therefore tightly regulated. For example, MLL is as-
sembled as a member of a large protein complex (with
≥29 proteins) containing lysine-specific demethylase 1
(LSD1, also known as KDM1a) [10], which can demeth-
ylate H3K4me1 and 2 (but not H3K4me3) and plays an
opposite role in keeping a balanced H3K4 methylation
status [11] (Additional file 1: Figure S1B). In MLL-
rearranged leukemia, the onco-MLL loses the SET
domain and is fused with one of the >70 documented
genes (Additional file 1: Figure S1C), with AF4, AF10,
AF9, and its homolog ENL being predominant (>70 %)
[6, 12]. The mechanism for MLL leukemia has been well
studied [9, 13, 14]. These MLL fusion partners are able
to recruit DOT1L, a histone H3 lysine 79 (H3K79)
methyltransferase (Additional file 1: Figure S1D). This
leads to aberrant H3K79 methylation at MLL target gene
loci, causing dysregulated gene expression (e.g., over-
expression of HoxA9 and Meis1) and eventually initi-
ation of the leukemia. Indeed, potent small molecule
inhibitors of DOT1L, developed by us [15–17] and
others [18–21], have been found to have selective activ-
ity against MLL leukemia.
LSD1 is a flavin adenine dinucleotide (FAD)-dependent
monoamine oxidase (MAO), and its mechanism of
catalysis is illustrated in Additional file 1: Figure S2 [11,
22]. The methyl group in H3K4me1 or 2 is removed by
FAD-mediated oxidation, after which FAD is regenerated
by oxidation with O2 to complete a catalytic cycle. The
biological function of LSD1 is crucial, as LSD1 knockout
in mice is embryonic lethal and conditional knockout
blocked hematopoiesis [23]. Overexpression of LSD1 was
found in several types of cancers (e.g., prostate and
breast), suggesting that LSD1 might be a drug target for
intervention [24–26]. Recently, LSD1 was reported to be
required for leukemia stem cells (LSC) with MLL-AF9
fusion oncogene [27]. Using cyclopropylamine-based LSD1
inhibitors also showed in vitro and in vivo activity against
MLL-AF9 leukemia. However, the compounds in the study
exhibited severe toxicity, with many of the experimental
mice dying of severe anemia/thrombocytopenia. More
studies are therefore needed to show that this chemo-
type of LSD1 inhibitors can be safely used in the
clinic [28, 29].
Here, we synthesized a series of cyclopropylamine-
based LSD1 inhibitors and found that these compounds
possess potent and selective activity against MLL-
rearranged leukemia, with their antileukemia activities
correlated with LSD1 inhibitory activity. In addition, we
show that one compound exhibited significant in vivo
activity in a mouse model of MLL leukemia without ob-
vious toxicities, showing that potent LSD1 inhibitors are
potentially useful therapeutics for this subtype of acute
leukemia. Molecular and cell biology studies were
performed to characterize these compounds in MLL-
rearranged leukemia as well as possible mechanism(s) of
action.
Results
LSD1 inhibitors exhibited potent antileukemia activity
A number of several chemotypes of LSD1 inhibitors have
been reported [30–37], among which cyclopropylamine-
containing compounds exhibited low nM IC50 values
against the enzyme. However, these compounds have not
been evaluated for their activity against leukemia cells. We
synthesized compounds 1–3 (Fig. 1a) and tested their
biochemical inhibition against recombinant human LSD1.
Choosing these three compounds was based on their
reported low nanometer inhibitory activity against LSD1
[30]. The LSD1 inhibition assay was performed with the
reaction rate (i.e., amount of the product H2O2, Additional
file 1: Figure S2) being quantitatively determined by
adding horseradish peroxidase (HRP) and a HRP fluores-
cence substrate Amplex red. Thus, compound 1 with a
flexible 4-benzyloxy group was found to be an extremely
potent inhibitor with an IC50 value of 9.8 nM (Table 1),
which almost quantitatively deactivates LSD1 (~30 nM in
the assay). Compound 2 having a rigid fluoropyridine sub-
stituent is also a potent inhibitor with an IC50 of 77 nM.
Compound 3 with a less bulky 4-Br group exhibited 2×
more activity (IC50 = 35 nM) than 2. These results are
comparable to those reported previously [30].
Next, these three compounds were tested for their
cellular activity against proliferation of MV4-11 leukemia
cells bearing MLL-AF4 fusion oncogene. As representa-
tively shown in Fig. 1b, unlike traditional chemotherapeu-
tics that exhibit cytotoxicity within 2 days, the LSD1
inhibitors did not significantly affect proliferation of
MV4-11 cells in a shorter period of time (e.g., 3 days),
depending on their concentrations. However, upon
incubation for ≥10 days, these compounds showed potent
activity against MV4-11 cells with EC50 values for
compounds 1–3 being 10, 84, and 20 nM, respectively
(Table 1). The slow antiproliferative action suggests that
these LSD1 inhibitors do not have general cytotoxicity,
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e.g., inhibition of DNA/RNA/protein biosynthesis that
affects all rapidly proliferating cells. Rather, similar to
DOT1L inhibitors [16, 18], a series of cellular events are
required for LSD1 inhibitors to inhibit cell growth, which
could include blocked H3K4 demethylation, downregula-
tion of leukemia-relevant genes, and depletion of
downstream effector proteins.
Antileukemia activity correlated with LSD1 inhibitory
activity
Given the potent activity of compounds 1–3, more
analogous compounds were investigated. While detailed
structure activity relationships of these compounds will
be described in a separate publication, we show the
antileukemia data of several representative compounds,
including compound 4 (Fig. 1a), which is a fragment of
compound 2 without the second substituent at the
amine-N atom. Compound 4 exhibited a good inhibitory
activity against LSD1 with an IC50 value of 5.3 μM
(Table 1), but it is ~70-fold less potent than compound
2, showing the that the second substituent of 2 plays an
important role in LSD1 inhibition. In addition, com-
pound 4 was also found to have a significantly reduced
antiproliferative activity (EC50, 1.4 μM) against MV4-11
leukemia cells.
Fourteen compounds (including compounds 1–4) with
a broad range of LSD1 inhibitory activities with IC50
values of 9.8 nM to >100 μM were selected and tested
against proliferation of MV4-11 leukemia cells. The
structures and biochemical IC50 values of compounds
5–14, as well as their antiproliferative EC50 values, are
summarized in Additional file 1: Table S1. Overall, as
shown in Fig. 1c, LSD1 inhibition (enzyme IC50 values)
for these 14 compounds was found to be well correlated
with their antiproliferation activity (EC50 values), with
the R2 value of 0.88. These results suggest that LSD1
Fig. 1 LSD1 inhibitors blocked proliferation of MV4-11 leukemia cells. a Structures of compounds 1–4. b Growth curves for MV4-11 cells with or
without treatment with compound 2 (*p < 0.01 with respect to the control). c Good correlation between enzyme IC50 values of LSD1 inhibitors
and their antiproliferative activities, showing a R2 of 0.88
Table 1 LSD1 inhibitory (IC50, μM) and antiproliferative (15-day treatment EC50, μM) activities for compounds 1–4
LSD1
IC50
MLL-rearranged leukemia Non-MLL leukemia cells Breast Prostate
MV4-11 Molm-13 NB4 U937 MCF-7 LNCaP
1 0.0098 0.010 0.096 19.4 18.9 1.6 3.7
2 0.077 0.084 0.32 18.9 34.6 6.6 10.0
3 0.035 0.020 0.18 >50 >50 13.5 29.9
4 5.3 1.4 12 >50 17.5 >50 >50
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could be the cellular target responsible for the cell
growth inhibition.
Potent and selective activity against MLL-rearranged
leukemia
We next examined the spectrum of antitumor activity
for compounds 1–4. These compounds were incubated
with a panel of six human leukemia and solid tumor cell
lines, including two MLL-rearranged leukemia cells
MV4-11 and Molm-13 containing fusion oncogenes
MLL-AF4 and -AF9, respectively. NB4 and U937
leukemia cells do not have an MLL translocation. Also
included in the studies are breast cancer MCF-7 and
prostate cancer LNCaP cells. Similar to their activities
against MV4-11, compounds 1–4 had no or negligible
activity against proliferation of all other tumor cells in a
3-day treatment. However, as summarized in Table 1,
potent LSD1 inhibitors 1–3 showed particularly high ac-
tivities against MLL-rearranged leukemia cells MV4-11
and Molm-13 with EC50 values of 10–320 nM. The cell
activities seem to be in line with the LSD1 inhibitory
activities, with compound 1 being the most potent
(EC50 = 10 and 96 nM against MV4-11 and Molm-13).
Moreover, less potent LSD1 inhibitor 4 was found to
possess considerably reduced activities against the two
MLL-rearranged leukemia cells (EC50 = 1.4 and 12 μM).
NB4 and U937 leukemia cells without an MLL trans-
location exhibited low susceptibility to the treatment with
compounds 1–3. The 15-day treatment EC50 values for
compounds 1–3 are ≥19 μM, showing that these com-
pounds have high selectivity (>108-fold) against MLL-
rearranged leukemia cells. LSD1 has been reported to be
overexpressed in breast and prostate cancers [24, 25]. The
most potent LSD1 inhibitor 1 showed good antiprolifera-
tive activity against MCF-7 (breast) and LNCaP (prostate)
cancer cells with 15-day EC50 values of 1.6 and 3.7 μM,
respectively. Compound 2 had moderate activity (15-day
EC50, 6.6 and 10 μM) against these two cells, while
compound 3 did not significantly affect MCF-7 and
LNCaP cells (15-day EC50 = 13.5 and 29.9 μM). These
results show that MLL-rearranged MV4-11 and Molm-13
leukemia cells are far more sensitive to LSD1 inhibition.
Activity against MAO-A/-B and selectivity for LSD1
The cyclopropylamine LSD1 inhibitors were generally de-
rived from MAO-A/-B inhibitor tranylcypromine, an anti-
depression drug. Because MAO-A and -B play important
roles in the degradation of neurotransmitters (e.g., sero-
tonin and dopamine) in the central nervous system, select-
ive inhibition for LSD1 is highly desirable. We tested
compounds 1–4 for their biochemical activity against
human MAO-A and -B, and the results are summarized
in Table 2. Compounds 1 and 2 exhibited only weak activ-
ity (IC50, 17.5–480 μM) against MAO-A and -B, showing
excellent selectivity for LSD1 inhibition of >1500-folds.
Compound 3 had moderate inhibitory activity (IC50, 7.3
and 16.3 μM) against these two MAO enzymes and it also
showed >200× selectivity for LSD1. However, compound
4 without the second amine-N substituent exhibited more
potent inhibitory activity against MAO-A and -B (IC50,
0.42 and 3.1 μM, respectively). These results indicate that
compounds 1 and 2 are highly potent and selective LSD1
inhibitors.
Cell activities of LSD1 inhibitors
Compounds 1 and 2 were selected for further biological
activity testing. MV4-11 cells were treated with these
two compounds for 3 days. Western blot experiments
showed that both compounds 1 and 2 can increase
cellular levels of H3K4me2 in a dose-dependent manner
(Fig. 2a), indicating that these compounds are cell
membrane permeable and inhibit LSD1 in MV4-11 cells.
In addition, these compounds did not seem to consist-
ently affect the global levels of H3K4me1 and H3K4me3.
Other researchers observed the similar results using a
different LSD1 inhibitor.
Next, we examined whether LSD1 inhibition can
block the expression of HoxA9 and Meis1, whose
overexpression has been observed in MLL-rearranged
leukemia [9, 18, 20]. As shown in Fig. 2b, treatment
with compounds 1 and 2 can significantly decrease
the expression of both HoxA9 and Meis1 in a dose-
dependent manner.
Third, compounds 1 and 2 were found to be able to
induce significant apoptosis of MV4-11 cells using
fluorescence-activated cell sorting (FACS)-based Annexin-
V assay. As shown in Fig. 2c and Additional file 1: Figures
S3 and S4, compound 1 at 30 nM can induce 12 % apop-
tosis on day 7 and showed an increased potency of 20 % on
day 14. At 300 nM, 1 exhibited more potent activity in
inducing apoptosis of MV4-11, being 13 % on day 7 and
26 % on day 14. Similarly, compound 2 at 0.1 μM induced
11 and 13 % apoptosis of MV4-11 cells in 7 and 14 days
(respectively). It promoted significantly more apoptosis (45
and 49 % for 7 and 14 days) at 1 μM. These results suggest
that LSD1 inhibition led to an increased methylation at
H3K4 and this epigenetic change suppressed the expression
of leukemia relevant genes and induced apoptosis of
MLL-rearranged leukemia cells.
Table 2 Inhibitory activity (IC50, μM) against MAO-A and -B for
compounds 1–4 and their selectivity indices for LSD1
LSD1 MAO-A MAO-B Selectivity index
1 0.0098 17.5 34.2 >1700
2 0.077 120 480 >1500
3 0.035 7.3 16.3 >208
4 5.3 0.42 3.1 <0.58
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Studies have shown that there are a small proportion of
stem-like cancer cells (also known as cancer stem cells)
within the bulk of cancer, which possess certain traits of
normal stem cells, e.g., self-renewal and ability to differen-
tiate [38, 39]. Importantly, only these stem-like cancer
cells can form new tumors when transplanted into a new
host, while the other non-stem cancer cells fail to do so.
These stem-like cancer cells are more drug resistant and
believed to be responsible for tumor metastasis and re-
lapse. We found that LSD1 inhibition can induce differen-
tiation of MV4-11 stem-like leukemia cells and inhibit cell
migration. CD14 and CD11b are two cell surface proteins
characteristic to differentiated macrophages/monocytes
[18]. As shown in Fig. 3a, treatment with compounds 1
and 2 for 12 days caused significantly increased cells
expressing high levels of CD14. Similarly, incubation with
2 led to considerably more CD11b+ cells (Fig. 3b). These
results indicate that LSD1 inhibition can induce differenti-
ation of stem-like leukemia cells to become more matured
macrophage-like cells. In addition, treatment with com-
pound 2 for 4 days led to reduced ability for MV4-11 cells
to migrate through a membrane with 8-μm pores (Fig. 3c),
showing that LSD1 inhibition could have the potential to
block tumor cell migration.
LSD1 inhibition reduced colony-forming ability of human
primary MLL leukemia cells
Colony-forming assay using non-serum culture media
represents a useful method to assess self-renewal cap-
acity of stem-like cancer cells [27, 40]. The number of
cell colonies formed in the assay reflects the proportion
of stem-like cells in a given number of cancer cells. To
make the assessment more clinically relevant, we deter-
mined the ability of compounds 1–3 to inhibit the
colony-forming ability of human primary leukemia cells
from an AML patient with MLL-ENL fusion oncogene;
104 primary leukemia cells were plated in Methocult
H4434 methylcellulose medium containing increasing
concentrations of compounds 1–3 and colonies in each
culture dish were counted after 14 days. As shown in
Fig. 3d, potent LSD1 inhibitors 1–3 were able to largely
reduce the numbers of cell colonies with EC50 values of
0.43, 0.52, and 0.48 μM, respectively, showing that LSD1
inhibition can impair the leukemia stem-like cells in the
clinical sample.
Synergy when combined with DOT1L inhibition
Previous biological studies have shown that H3K79
methyltransferase DOT1L is a drug target for MLL-
rearranged leukemia [9, 16, 18]. Medicinal chemistry by
us and others has identified several highly potent
DOT1L inhibitors [15–21]. SYC-522 (Additional file 1:
Figure S5) is a potent and specific inhibitor of DOT1L
with Ki of 0.5 nM [16]. In our previous work, it can
inhibit the H3K79 methylation in MV4-11 cells with an
IC50 of ~200 nM [17]. SYC-522 also selectively blocked
proliferation of MLL-rearranged leukemia cells, includ-
ing MV4-11 and Molm-13 with the EC50 values of ~4
and 7 μM [16].
We investigated the combination of LSD1 and DOT1L
inhibition in MV4-11 and Molm-13 cells. These cells
were treated with a matrix of increasing concentrations
(from 0 to 0.1×, 0.33×, 1×, 3×, and 10 × EC50 for each in-
dividual compound) of compound 1 (or 2) and SYC-522
Fig. 2 Dose-dependent biological activities of compounds 1 and 2 in MV4-11 cells. a 1 and 2 caused increased levels of H3K4me2, while these
compounds seem not to affect H3K4me1 and me3 significantly. b 1 (upper) and 2 (lower panel) reduced gene expression of HoxA9 and Meis1
whose overexpression is characteristic to MLL-rearranged leukemia (*p < 0.05 with respect to the control). c 1 and 2 induced considerable
amounts of apoptosis in 7 or 14 days
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for 15 days. Cell viability in each well was determined and
data were analyzed by the program CompuSyn, which
calculates the combination index (CI) for each drug com-
bination [41]. The combinations with CI <1 indicate syn-
ergism for the two drugs, while those with CI = 1 show
additive effect and those with CI >1 represent antagonism.
As shown in Fig. 4a, combinations of compounds 2 and
SYC-522 exhibited strong synergy in inhibiting prolifera-
tion of MV4-11 cells, with the CI values ranging from
0.13 to 0.36. Similarly, combinations of compounds 1 and
SYC-522 also achieved strong synergy against Molm-13
cells (Fig. 4b). These results suggest that combination
inhibition of these two enzymes can achieve synergism
against this subtype of cancer.
Compound 1 exhibited significant in vivo antileukemia
activity without overt toxicity
Given its very high cellular activity, compound 1 was
tested for its in vivo antileukemia activity in a mouse
model of MV4-11 leukemia. Previous in vivo pharma-
cokinetics studies of compound 1 showed that it is
degraded rapidly in mice, having a short half-life
(~1 h) in the plasma [30]. Continuous infusion of 1
using a subcutaneously implanted osmotic pump was
used for in vivo studies to avoid the unfavorable
pharmacokinetics because this route may provide a
stable plasma drug concentration. Compound 1 at 2.5
and 5 mg/kg/day for 28 days did not cause weight
losses as well as any visible signs of toxicity in mice.
Choosing 28-day drug administration was because of
the slow antiproliferation activity of compound 1. A
blood test on day 28 showed no significant differences
in blood cell counts as well as hemoglobin between
mice in the treatment and control groups (Fig. 5a).
A mouse model of systemic MV4-11 leukemia was
established by injecting 107 MV4-11 cells/mouse intra-
venously through the tail veil into NOD-SCID mice with
an engraftment rate of 100 %. After 2 weeks, human
CD33+/CD45+ leukemia cells (0.1–0.5 %) can be de-
tected by FACS in blood samples of the mice. The dis-
ease progressed rapidly, causing deaths in ~6 weeks after
leukemia transplantation. Thus, upon detection of MV4-
11 engraftments, mice were randomly separated into
treatment and control groups. Mice (N = 5) were treated
with 1 using dosages of 2.5 and 5 mg/kg/day for
28 days, after which mice were sacrificed and their
bone marrow, spleen, and blood were analyzed for hu-
man CD33+/CD45+ leukemia cells. As shown in Fig. 5b,
compound 1 was able to significantly inhibit the pro-
gression of the leukemia. The lower dose treatment
Fig. 3 LSD1 inhibition promoted differentiation and inhibited cell migration and self-renewal. a Treatment of MV4-11 cells with compounds 1
and 2 for 12 days caused >90 % cell populations expressing high levels of CD14, a cell surface protein characteristic for macrophages/monocytes.
b Treatment of MV4-11 cells with 2 led to significantly more cells expressing high levels of CD11b, a cell surface protein for macrophages/monocytes.
c Treatment with 2 significantly reduced numbers of MV4-11 cells that can migrate through a membrane with 8-μm pores (*p < 0.05 with respect to
the control). d Treatment of human primary leukemia cells (from an MLL-rearranged leukemia patient) with LSD1 inhibitors 1–3 potently inhibited the
colony-forming ability with EC50 values of 0.43, 0.52, and 0.48 μM, respectively
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reduced MV4-11 leukemia cells by 80 % in the bone
marrow (averaging 6.7 % in the treatment vs. 33.6 % in
control group). Similarly, compound 1 caused 81 and
92 % less leukemia cells in the spleen and blood,
respectively. The antitumor effects were more pro-
nounced in the higher dose treatment group, achieving
96, 89, and 99 % inhibition rates in the bone marrow,
spleen, and blood, respectively. In addition, large meta-
static or invasive tumors in the gastrointestinal tract
and ovaries were observed in the control mice, while
none were visible in the treatment groups. In another
set of antileukemia activity evaluation, survival experi-
ments showed that compound 1 at the 2.5 and 5 mg/kg
dosages can significantly prolong the lifespan of the
leukemia-bearing mice (p < 0.05, Fig. 5c). The median
survivals for the control and 2.5 mg/kg treatment group
were 34.5 and 43 days, respectively. The higher dosage
treatment caused an increased antitumor efficacy, with
the median survivals for the two groups being 45 and
60 days, respectively. These results demonstrate that
LSD1 inhibitors have significant in vivo antitumor
activity and are potentially useful therapeutics for
MLL-rearranged leukemia.
Microarray studies of LSD1 inhibition
Since methylated H3K4 is an important histone biomarker
for gene regulation, we performed microarray studies to
determine how potent and selective LSD1 inhibitors 1 and
2, which were found to increase H3K4me2, affect gene ex-
pression in MV4-11 leukemia cells. In addition, this profil-
ing could help find the mechanism(s) by which these
compounds inhibit proliferation, induce differentiation,
and cause apoptosis of the leukemia cells.
To this end, triplicate samples of MV4-11 cells were
treated with compounds 1 and 2 and the RNA of these
samples was isolated, amplified, and hybridized to Illu-
mina HT-12 microarrays. The microarray data were log2-
transformed and normalized to have the same median
values for comparative analysis. Moderate t test was ap-
plied to search for genes that were differentially expressed
between the control and compound treated samples, using
the filter thresholds of p values <0.05 and fold changes >4.
Compared to the untreated controls, compounds 1 and 2
were found to cause highly similar changes in gene ex-
pression pattern (Additional file 1: Figure S6) despite their
different chemical structures, suggesting that LSD1, the
common target of these two compounds, is responsible
for the cellular activities. Next, we used gene set enrich-
ment analysis (GSEA) in an effort to find the possible
mechanism(s) for the LSD1 inhibition-mediated antileuke-
mia activity. Expression of several gene sets/pathways re-
lated to hematopoietic differentiation as well as apoptosis
was found to be significantly affected by LSD1 inhibition.
As shown in Fig. 6a–c and Additional file 1: S7A–C, treat-
ment with compounds 1 and 2 resulted in significant
upregulation of the gene sets of hematopoietic cell lineage
(HSA04640), leukocyte differentiation (GO:0002521),
and hematopoietic or lymphoid organ development
(GO:0048534), whose expression is important for the
differentiation of hematopoietic stem or progenitor cells
to become more matured lineages of blood cells as well as
the development of hematopoietic organs. These results
are consistent with our experimental observations show-
ing that compounds 1 and 2 promoted considerable dif-
ferentiation of MV4-11 cells. In addition, as shown in
Fig. 6d and Additional file 1: S7D, the two LSD1 inhibitors
also caused significant upregulation of the pro-apoptotic
gene set of regulation of programmed cell death
(GO:0043067), which could lead to the observed increased
apoptosis of MV4-11 cells upon treatment of these
compounds.
Discussion
MLL translocations are found in ~75 % infant and 10 %
children/adult acute leukemia showing a poor prognosis,
Fig. 4 Combination of LSD1 and DOT1L inhibition caused
synergistic effects against proliferation of MLL-rearranged leukemia
cells. a Combination treatment of MV4-11 cells with compounds
2 and SYC-522 exhibited combination index (CI) values of 0.13–0.36.
b Combination treatment of Molm-13 cells with compounds 1 and
SYC-522 showed combination index (CI) values of 0.01–0.61. CI
values <1 indicate synergism, while those =1 and >1 show additive
effect and antagonism, respectively
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with 5-year event-free survivals being <40 % [3–5]. The
phenotype of MLL-rearranged leukemias can be ALL,
AML, or mixed lineage leukemia. However, despite the
different phenotypes as well as the variety of fusion part-
ner genes (>70), this subtype of acute leukemias show a
similar gene expression profile [42]. Therefore, MLL
translocations can serve as a distinct biomarker in the
clinic as well as for drug discovery and development
[43]. There is a pressing need to find new drugs, espe-
cially less toxic therapeutics targeting onco-MLL, which
loses the C-terminal SET domain that methylates H3K4.
LSD1, which is able to demethylate H3K4me1 and 2, has
been found in the MLL transcription complex and coun-
teracts the SET domain of MLL. It is therefore assumed
that MLL and LSD1 can keep a balanced methylation
levels at H3K4, which is a critical “histone code” for
active transcription [7, 8]. In MLL-rearranged leukemia,
the balance in H3K4 methylation is impaired. In
addition, studies have shown the majority of MLL fusion
genes, including AF4, AF9, AF10, and ENL, can recruit
DOT1L and methylate H3K79. This aberrant histone
methylation at the MLL target gene loci causes overex-
pression of many Hox genes (e.g., HoxA7, HoxA9, and
Meis1) that eventually cause leukemia initiation. More
intriguing is that a recent report showed that the H3K4
methylation function of the wild-type MLL in the other
allele is essential for MLL-rearranged leukemia [44]. It
seems that the complicated “histone codes” at H3K4 and
K79 in this malignancy need to be corrected. Pharmaco-
logical inhibition of DOT1L has been found to be an ef-
fective approach to the treatment of this subtype of
leukemia, due to reduced H3K79 methylation levels that
inhibit expression of the above leukemia relevant genes.
A potent DOT1L inhibitor has been in clinical trials
against MLL-rearranged leukemia [20]. More recently,
LSD1 has been suggested to be a potential drug target
for MLL-rearranged leukemia. However, as described in
the “Background” section, more studies using potent and
selective LSD1 inhibitors are needed to further validate
this hypothesis.
In this work, a series of potent LSD1 inhibitors were
synthesized and found to have very potent activity
against proliferation of MLL-rearranged leukemia cells
MV4-11 and Molm-13 with EC50 values of 10–320 nM,
while these compounds had no or considerably weak-
ened activity against proliferation of several other
leukemia and solid tumor cells. Next, more medicinal
chemistry studies showed that antileukemia activity of
these compounds correlated with their LSD1 inhibitory
activity, suggesting that LSD1 is the cellular target.
Excellent LSD1 selectivity (200–>1,000-folds) against
related MAO-A and -B enzymes is also a desirable feature
Fig. 5 In vivo activities of compound 1 in a systemic mouse model of MV4-11 leukemia. a Treatment of NOD-SCID mice with 1 caused no significant
changes in blood cell counts, suggesting no obvious toxicities. b Compound 1 (2.5 and 5 mg/kg/day for 28 days) significantly reduced MV4-11
leukemia cells in the bone marrow, spleen, and peripheral blood, with the higher dosage showing more pronounced antitumor effects (*p < 0.05 with
respect to the control). c Treatment with 1 (2.5 and 5 mg/kg/day for 28 days) significantly prolonged the life span of mice transplanted with MV4-11
leukemia (p < 0.05 and 0.01, respectively). The median survivals for the control and 2.5 mg/kg treatment group were 34.5 and 43 days, respectively. The
higher dosage treatment caused an increased antitumor efficacy, with the median survivals for the two groups being 45 and 60 days, respectively
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of these compounds in the context of drug discovery. Two
most potent LSD1 inhibitors 1 and 2 were found to be cell
membrane permeable and can significantly increase the
levels of H3K4me2 in MV4-11 cells. The most potent
compound 1 showed significant antitumor activity in a
systemic MV4-11 leukemia mouse model without overt
toxicities to mice. Upon treatment (5 mg/kg), the
leukemia burdens in the bone marrow, spleen, and periph-
eral blood were inhibited by >89 % and the life spans for
the experimental animals were significantly prolonged,
showing the potential of this class of compounds to be-
come clinically useful therapeutics for MLL-rearranged
leukemia.
More biological studies demonstrated that LSD1 inhibi-
tors 1 and 2 were able to downregulate the expression of
leukemia-relevant genes HoxA9 and Meis1, induce apop-
tosis, and differentiation. In addition, the ability of these
compounds to inhibit colony-forming ability of primary
MLL leukemia patient cells suggested that LSD1 inhib-
ition impaired self-renewal of the stem-like leukemia cells.
Microarray studies showed that LSD1 inhibition by com-
pounds 1 and 2 caused significant upregulation of several
gene sets that promote hematopoietic differentiation and
apoptosis, which revealed the underlying mechanisms of
LSD1 inhibition in MV4-11 leukemia cells.
Given the promising in vitro and in vivo antitumor
activity, compound 1 represents a potential thera-
peutic agent against MLL-rearranged leukemia. MLL
gene rearrangement could serve as a criterion for patient
recruitment in a future clinical trial. More preclinical
evaluation, especially animal pharmacokinetic studies,
should be performed to further evaluate whether 1 as well
as other LSD1 inhibitors are viable drug candidates. In
addition, MLL translocations can also be found in a small
portion (<1 %) of chronical myeloid leukemia (CML)
patients [45]. Although rare, these patients had a low re-
sponse rate to BCR-ABL inhibitor therapies and a poor
prognosis. Evaluation of potent inhibitors of LSD1 (or
DOT1L) against this molecular subtype of CML might
be useful. It is also noted that LSD1 has been found to
play a critical role in development [23]. Germline
knockout of LSD1 is embryonically lethal. Conditional
knockout in adult mice caused blocked hematopoiesis
and pancytopenia. In addition to H3K4 and H3K9 [46]
as well as other non-histone proteins such as DNMT1
(DNA methyltransferase 1) [47] are substrates of LSD1.
For example, LSD1 is of importance to the stability, in-
tegrity, and function of DNMT1, an enzyme that main-
tains appropriate DNA methylation. LSD1 knockdown
was found to cause global DNA hypomethylation [47].
Fig. 6 Microarray results of LSD1 inhibition in MV4-11 cells. Upon treatment with compound 1 (100 nM), GSEA plots showed significant upregulation
of the gene sets of a hematopoietic cell lineage (HSA04640), b leukocyte differentiation (GO:0002521), and c hematopoietic or lymphoid
organ development (GO:0048534), as well as d the pro-apoptotic gene set of regulation of programmed cell death (GO:0043067). The right panels in
a–d are heat maps showing expression levels of selected genes in the leading edges of the GSEA plots
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These lines of evidence raise a safety concern of LSD1 in-
hibition. Nonetheless, another conditional LSD1 knockout
mouse model study showed that after termination of LSD1
knockout, the impaired hematopoiesis can be fully recov-
ered in the experimental animals [48]. Here, we further
demonstrated that potent LSD1 inhibitor 1 can be safely ad-
ministered (5 mg/kg/day) for an extended period of 28 days
without overt toxicities to mice. Significant antitumor
activity has also been observed. These experiments strongly
suggest that there is a sufficient therapeutic window for
pharmacological inhibition of LSD1 targeting leukemia.
Moreover, combination therapy could be a viable ap-
proach to further reduce the potential toxicity issue of LSD1
inhibitors. We show in this study that combination treat-
ments of LSD1 inhibitors with a DOT1L inhibitor SYC-522
exhibited strong synergism against proliferation of MLL-
rearranged leukemia cells, presumably because H3K79
hypermethylation is closely associated with imbalanced
H3K4 methylation in MLL-rearranged leukemia. In addition,
since inhibition of LSD1 also caused DNA hypomethylation,
the combination of an LSD1 inhibitor with a DNMT inhibi-
tor (e.g., 5-azacitidine or decitabine) could also be effective.
Conclusions
LSD1 is a drug target for MLL-rearranged leukemia and
small molecule LSD1 inhibitors are potential therapeu-
tics for the malignancy.
Methods
Cell lines and primary cells
MLL-rearranged leukemia cells MV4-11 and Molm-13 were
obtained from ATCC (American Type Culture Collection,
Manassas, VA) and DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Braunschweig,
Germany), respectively. Non-MLL leukemia cells NB4 and
U937 were described in our previous publications [49, 50].
The primary samples were obtained from patients who were
treated at Texas Children’s Cancer Center and whose parents
consented to the storage of remainder pheresis or bone mar-
row material for future research, in accordance with the IRB-
approved protocol H-3342. The primary leukemia sample is
the remainder bone marrow from a child diagnosed with
AML with t(11;19).
Compound synthesis and characterization
All chemicals for synthesis were purchased from Alfa Aesar
(Ward Hill, MA) or Aldrich (Milwaukee, WI). The com-
pound identity was characterized by 1H NMR on a Varian
(Palo Alto, CA) 400-MR spectrometer. The purities of
synthesized compounds were determined by a Shimadzu
Prominence HPLC with a Zorbax C18 (or C8) column
(4.6 × 250 mm) monitored by UV at 254 nm. The purities of
the reported compounds were found to be >95 %. Synthesis
and characterization of compounds 1–4 can be found in
Additional file 1.
LSD1 enzyme inhibition
Human LSD1 catalytic domain (172-833) was cloned and
inserted into pGEX-KG vector. The correctness of insert
was verified by sequencing. BL21-CodonPlus strain (Agi-
lent) was transformed with the pGEX-KG-LSD1 plasmid
and cultured at 37 °C in LB medium containing ampicillin
(50 μg/mL) and chloramphenicol (34 μg/mL). Upon reach-
ing an optical density of ~0.9 at 600 nm, LSD1 expression
was induced by adding 0.2 mM isopropylthiogalactoside at
25 °C for 20 h. Cells were harvested, lysed, and centrifuged
at 20,000 rpm for 20 min, and the supernatant was
collected and subjected to an affinity column chromatog-
raphy using the glutathione sepharose resin. The GST-
LSD1 fusion protein was eluted with 10 mM of glutathione
solution and purified by chromatography with a Superdex
200 gel filtration column with ~90 % purity (SDS-PAGE).
The inhibition assay for the recombinant LSD1 was per-
formed using a published protocol [30], with the reaction
rate (i.e., amount of the product H2O2) being quantitatively
determined by adding HRP and a HRP fluorescence sub-
strate Amplex red. In a 96-well microplate, an increasing
concentration (1 nm–100 μM) of an inhibitor was incubated
with 30 nM LSD1 in 50 mM phosphate buffer (pH= 7.0)
containing 0.01 % Brij-35 for 30 min at 25 °C, before
initiation of the reaction by adding 10 μM of dimethylated
peptide substrate ARTK(Me2)QTARKSTGGKAPRKQKA
(Km~ 10 μM). The total volume of the reaction mixture is
60 μL. After 20 min, 60-μL solution containing HRP (0.01
unit) and Amplex red (80 μM) was added and the fluores-
cence of each well was determined using a Beckman DTX-
880 microplate reader (excitation at 535 and emission at
595 nm). Data were imported into Prism 5.0 (GraphPad),
and the IC50 values were calculated by using the sigmoidal
dose response curve fitting in the software. The reported
IC50s were the mean values of at least three independent
experiments.
Inhibition of MAO-A/-B
Recombinant human MAO-A and -B were purchased
from Sigma. The inhibitory activity was determined
using MAO-Glo assay kit (Promega). In brief, following
the manufacturer’s protocol, assays were performed in
384-well white plates (Corning) using MAO-A or -B
(100 nM) with a final volume of 20 μL. Reactions were
quenched after 60 min by adding reconstituted luciferin
detection reagent (20 μL/well); 20 min after addition of
the detection reagent, the luminescence of each well was
measured using Beckman DTX-880 microplate reader.
IC50 calculation was similar to that of LSD1.
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Antiproliferation assay
Proliferation inhibition assay for suspension leukemia
cells was performed using an XTT assay kit (Roche) with
our previously described method. Proliferation inhibition
assay for solid tumor cell lines MCF-7 and LNCaP was
performed using our previous described MTT assay. The
antiproliferation EC50 values were determined by Prism,
and the reported results were the mean values of at least
three independent experiments.
Western blot
With increasing concentrations of a compound for 5 days,
106 cells/well were incubated and histones extracted with the
EpiQuik™ Total Histone Extraction Kit (Epigentek) according
to the manufacturer’s protocol. Equal amounts of histones
(2 μg) were separated on SDS-PAGE and transferred to
PVDF membranes. The blots were probed with H3K4-Me2
and H3 primary antibodies (Cell Signaling), followed by
antirabbit IgG (Thermo Scientific) secondary antibodies.
Flow cytometry
For Annexin V apoptosis assay, 105 cells/well were incu-
bated with increasing concentrations of a compound for 7
or 14 days. Apoptosis was determined using the FITC
Annexin V Apoptosis Detection Kit I (BD Bioscience)
using the manufacturer’s protocol. For other FACS assays,
cells were labeled with fluorochrome-conjugated mono-
clonal antibodies against human CD14, CD11b, CD45, or
CD33 (BD Biosciences) according to the manufacturer’s
recommendation. Cells were analyzed using a FACS Cali-
bur (BD Biosciences/Applied Biosystems), and data were
processed using the program Flowjo (version7.6.5).
Quantitative real-time PCR
For 3 days, 104 cells/well were incubated with a com-
pound, and the RNA was extracted from cells using
RNeasy mini kit (QIAGEN); 100–1000 ng of total RNA
was reverse transcribed using iScript™ Reverse Transcrip-
tion Supermix (Bio-Rad) using the manufacturer’s proto-
col. Quantitative real-time PCR was carried out using Fast
SYBR Green Master Mix (Applied Biosystems) according
to the manufacturer’s instructions. Measurements were
performed in triplicate, using GAPDH as the reference
gene. Real-time PCR was performed using Biosystems
Step One Plus detection system. The following sequences









Human MLL-rearranged AML samples will be obtained
from the Children’s Oncology Group (COG) Biopathol-
ogy Center, in accordance with the IRB-approved proto-
col H-24170. The colony-forming assay was performed
according to our previously published method [40].
After 14 days, the colony number of each culture dish
was counted and imported into Prism 5.0 and EC50
values were determined by using the sigmoidal dose re-
sponse curve fitting in the software.
Cell migration assays
Cell migration assay was performed in a 24-well transwell
plate with 8-μm polyethylene terephthalate membrane fil-
ters (Falcon cell culture insert; Becton-Dickinson) separat-
ing the lower from the upper culture chambers, according
to the manufacturer’s instructions. In brief, MV4-11 cells
were treated with or without compound 2 (50 nM and
1 μM) for 4 days. Triplicate samples of 106 cells/well were
plated in the upper chamber containing serum-free
RPMI-1640. RPMI-1640 supplemented with 10 % FBS in
the bottom chamber was used to attract cells to move
through the filter. Cells were allowed to incubate at 37 °C
for 4 h, after which the cells that had migrated through
the pores were harvested in the bottom chamber and
counted. Results are presented as means ± s.d.
In vivo activity studies
All of the mouse studies were conducted in strict com-
pliance with the IRB-approved protocol. NOD-SCID
mice (4 to 6 weeks old) were obtained from Jackson lab
(Bar Harbor, ME, USA) and maintained under specific
pathogen-free conditions; 107 MV4-11 cells/mouse were
injected intravenously through the tail veil, and
animal weights were monitored twice a week. After
2 weeks when the blood samples showing 0.1–0.5 %
CD45+/CD33+ human leukemia cells, mice were ran-
domly segregated into control and treatment groups. Mice
in the treatment group were implanted subcutaneously in
osmotic pumps (Alzet model 2004) containing 1.75 mg of
compound 1 in 200 μL of PBS/DMSO (1:1). Animals were
sacrificed when >20 % weight loss, hunched posture,
ruffled fur, or inactivity was observed. The peripheral
blood, spleen, and bone marrow cells were isolated and
tested for CD45+/CD33+ using FACS. Log-rank analysis
was used to determine statistical significance of the
survival curves using Prism 5.0.
RNA amplification and microarray data analysis
For 7 days, 105 cells/well were incubated with compounds.
Cells were treated with Trizol® Reagent, frozen in liquid
nitrogen, and shipped to Asuragen, Inc. (Austin, TX) for
microarray experiments. RNA from these samples was
isolated, amplified, and hybridized to Illumina Human
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HT-12 v4 arrays according to the manufacturer’s protocol.
Microarray data were log2 transformed and normalized to
have the same median for all the arrays. Moderate t statis-
tics were used to find genes that were differentially
expressed between the samples of interest. Benjamini and
Hochberg method was used to correct for multiple com-
parisons. R and Bioconductor packages were applied for
all the statistical analyses (see http://cran.us.r-project.org/,
http://www.bioconductor.org/). GSEA analysis was
performed using GSEA software from Broad Institute
(Boston, MA).
Additional file
Additional file 1: Figures S1-S7, Table S1 and Compound synthesis
and characterization. (PDF 1450 kb)
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